Sekar Kathiresan, Verve Therapeutics CEO
Updated: Verve's landmark base editing trial for cardio drug runs into FDA hold
Four months after kicking off the first-ever base editing trial in humans, Verve Therapeutics is running up against a regulatory wall.
The FDA placed Verve …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
